866-997-4948(US-Canada Toll Free)

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 72 Pages

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017

Summary

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Respiratory and Undisclosed which include indications Basal Cell Carcinoma (Basal Cell Epithelioma), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Medulloblastoma, Cirrhosis, Esophageal Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Peritoneal Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoothened Homolog (Protein Gx or SMO) - Overview
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
BeiGene Ltd
F. Hoffmann-La Roche Ltd
Ignyta Inc
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
Pfizer Inc
Redx Pharma Plc
Sun Pharma Advanced Research Company Ltd
Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
glasdegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smoothened Homolog (Protein Gx or SMO) - Dormant Products
Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
Featured News & Press Releases
May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Nov 28, 2016: Curis Announces Full Approval of Roches Erivedge in the European Union
Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial
Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial
Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting
Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS
Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment
Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting
May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer
Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by BeiGene Ltd, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by IMPACT Therapeutics Inc, H2 2017
Pipeline by Mayne Pharma Group Ltd, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Redx Pharma Plc, H2 2017
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *